MorphoSys AG and Vivoryon Therapeutics AG announced that they have entered into an agreement under the terms of which MorphoSys has obtained an exclusive option to license Vivoryon's small molecule QPCTL inhibitors in the field of oncology. The option covers worldwide development and commercializati...
Original Article: MorphoSys and Vivoryon Therapeutics Enter Agreement in Immuno-Oncology